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Abstract
Background: Chagas’ disease is a human tropical parasitic illness and a subset of the chronic patients develop
megaesophagus or megacolon. The esophagus dilation is known as chagasic megaesophagus (CM) and one of the
severe late consequences of CM is the increased risk for esophageal carcinoma (ESCC). Based on the association
between CM and ESCC, we investigated whether genes frequently showing unbalanced copy numbers in ESCC
were altered in CM by fluorescence in situ (FISH) technology.
Methods: A total of 50 formalin-fixed, paraffin-embedded esophageal mucosa specimens (40 from Chagas
megaesophagus-CM, and 10 normal esophageal mucosa-NM) were analyzed. DNA FISH probes were tested for
FHIT, TP63, PIK3CA, EGFR, FGFR1, MYC, CDKN2A, YES1 and NCOA3 genes, and centromeric sequences from
chromosomes 3, 7 and 9.
Results: No differences between superficial and basal layers of the epithelial mucosa were found, except for loss of
copy number of EGFR in the esophageal basal layer of CM group. Mean copy number of CDKN2A and CEP9 and
frequency of nuclei with loss of PIK3CA were significantly different in the CM group compared with normal mucosa
and marginal levels of deletions in TP63, FHIT, PIK3CA, EGFR, CDKN2A, YES and gains at PIK3CA, TP63, FGFR1, MYC,
CDNK2A and NCOA3 were detected in few CM cases, mainly with dilation grades III and IV. All changes occurred at
very low levels.
Conclusions: Genomic imbalances common in esophageal carcinomas are not present in chagasic
megaesophagus suggesting that these features will not be effective markers for risk assessment of ESCC in patients
with chagasic megaesophagus.
Background
Chagas’ disease is a human tropical parasitic disease
which occurs in the Americas, particularly in South
America. It affects 16 to 18 million people in tropical
and subtropical countries of Latin America [1]; in Brazil,
the number of cases has reached 6 million [2]. During
the chronic phase, 6 to 7% of chagasic patients develop
mega syndromes represented by muscular hypertrophy
and dilation of the esophagus or colon, in consequence
of destruction of the myoenteric and submucous plexus
by the protozoan Trypanosoma cruzi[3]. The digestive
forms, megaesophagus or megacolon may be observed
in advanced stages of the disease [3].
Megaesophagus is consequence of achalasia character-
ized by the destruction or lack of intramural nerve
plexus, which determines the absence of peristalsis and
lack of openness of the lower esophageal sphincter in
response to swallowing. In consequence, food retention
or esophageal stasis occurs, leading to the appearance of
chronic esophagitis, acanthosis, paraceratose and leuko-
plakia, possibly pre-cancerous lesions [3]. One of the
severe late consequences of chagasic megaesophagus is
the increased risk (3% to 8%) of developing esophageal
squamous cell carcinoma (ESCC) compared to when
megaesophagus is not present [4-6]. Also, ESCC devel-
ops in chagasic megaesophagus patients at a younger
age than in those without this disease [5]. The detection
of cancer in these patients is difficult because the symp-
toms are hidden by the severe dysphagia caused by
megaesophagus [7]. The diagnosis is frequently late,
when the patient is in advanced stage, resulting in a
poor prognosis [5]. * Correspondence: anabete@ibilce.unesp.br
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malignancy and ranks the sixth most frequent cause of
death worldwide, but its incidence varies largely among
regions [8]. Approximately 16,470 new cases of esopha-
geal carcinoma were expected in the US population in
2009 [9]. The Brazilian National Institute of Research in
Cancer (INCA) reported that esophageal cancer was the
sixth in the cancer rank mortality in 2000 with 5,307
deaths. The estimated incidence in 2008 was 10550 new
cases with an incidence per 100 thousand individuals
varying among geographical areas from 1.04 to 19.07 in
males and 0.39 to 7.58 in females [8].
In ESCC, molecular cytogenetic techniques have
shown common occurrence of unbalanced genomic
regions involved in amplification of oncogenes and dele-
tion of tumor suppressor genes [10,11]. However, stu-
dies in benign esophageal lesions with precancerous
potential as megaesophagus are scarce. This study used
FISH technique to investigate chagasic megaesophagus
for genomic status of genes frequently unbalanced in
ESCC with the goal of identifying potential markers of
risk to cancer. The selected targets included FHIT,
TP63, PIK3CA, EGFR, FGFR1, MYC, CDKN2A, YES1
and NCOA3 genes, all of which have been reported as
occurring in significantly abnormal numbers in ESCC
[12-19].
Methods
Subjects
Formalin-fixed, paraffin-embedded (FFPE) esophageal
mucosa was obtained from 40 patients with diagnosis of
chagasic megaesophagus (CM) who underwent middle
and distal esophageal biopsies from 2000 to 2007 at the
Hospital de Base (São José do Rio Preto, SP, Brazil). The
study was approved by the Institution Research Ethical
Committee (CEP) and by the Brazilian National
Research Ethics Committee (CONEP), and written
informed consent was obtained from all patients.
Among the 40 CM patients, the mean age was 62.5
years (range: 40 - 83 years) and 20 were male; 29 were
never-alcoholics, 3 former-alcoholics (≥5 years of absti-
nence) and 8 current alcoholics; 18 were never-smokers,
6f o r m e r - s m o k e r s( ≥5 years of quitting) and 16 were
current smokers. The megaesophagus diagnosis was
made by physical examination, and radiologic and endo-
scopic study of esophageal motility by manometry [3].
The dilation grade of megaesophagus was classified as I
to IV, based on the retention of contrast, diameter, toni-
city of the lower sphincter and the length of the esopha-
gus body [20]. This study cohort included 5 patients
with megaesophagus grade I, 7 with grade II, 17 with
grade III and 11 with grade IV. The CM group was fol-
lowed for 2 to 4 years (median follow up = 2,8 years)
and no one developed ESCC, probably due to the short
follow up of patients.
The control group (NM) was composed by 10 health
subjects who were submitted to endoscopy under suspi-
cion of dyspepsia, but the histopathological analysis has
shown normal esophageal mucosa. In this group, the
mean age was 42.4 (range: 26 - 67 years); 3 individuals
were male and 7 female; 6 were never-alcoholics and
four current alcoholics; 7 were never smokers and 3
current smokers.
Fluorescence In Situ Hybridization (FISH)
Serial 4 μm-thick sections were cut from paraffin-
embedded blocks and mounted in glass slides pre-trea-
ted with 3-aminopropyl-triethoxysilane/acetone solution.
Specimens were incubated at 56°C overnight, deparaffi-
nized in Citrisolv washes (Fisher Brand, Cat #22-
143975) (three times for 10 min each), and dehydrated
in 100% ethanol. After incubation in 2 × SSC (Sodium
chloride, sodium citrate solution, pH 7.0) at 75°C, sec-
tions were digested with proteinase K (0.25 mg/ml in 2
× SSC, pH 7.0) at 45°C, rinsed in 2 × SSC (pH 7.0) at
room temperature for 5 min and dehydrated in an etha-
nol series.
The following DNA probe sets were used: (a) EGFR/
CEP7 (Abbott Molecular, Cat. # 32-191053, EGFR
mapped at 7p12), P16/CEP9 (Abbott Molecular, Cat. #
32-190078, CDKN2A mapped at 9p12), c-MYC (Abbott
Molecular, Cat. # 32-190006, MYC mapped at 8q24)/
homebrew FGFR1 (RP11-350N15, mapped at 8p12), and
the homebrew probes FHIT (CTD-2196D15, mapped at
3p14.2)/centromere 3 (pa 3.5), TP63 (RP11-373I6,
mapped at 3q28)/PIK3CA (RP11-245C23, mapped at
3q26) and YES1 (RP11-769O8, mapped at 18q11.31)/
NCOA3 (RP11-456N23, mapped at 20q12). The home-
brew probes were prepared from BAC clones and puri-
fied DNA was labeled using the Nick Translation Kit
(Abbott Molecular Cat. # 32-801300). In each probe set,
one target was labeled with green fluorophore (Spec-
trum Green) and the other with red fluorophore (Spec-
trum Red). The probe set was applied to the selected
area, which was covered with glass coverslip and sealed
with rubber cement. Co-denaturation of chromosomal
and probe DNAs was performed at 85°C for 10 min and
hybridization was allowed to occur in a humidified
chamber at 37°C for 20-24 h for commercial probes and
40-48 h for homebrew probes. After hybridization, the
slides were washed twice in 2 × SSC/0.3% NP-40 at 73°
C for 2 min, rinsed in 2 × SSC at room temperature for
2 min, dehydrated in ethanol series, air dried and coun-
terstained with 4’,6 ’-diamino-2-phenylindole - DAPI,
(0.3 ug/ml in Vectashield Mounting Medium, Vector,
Cat. # H-1200).
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Page 2 of 10Fluorescence signals were scored in epifluorescence
microscope using single band filters for DAPI, FITC
(fluorescein), and Texas red, double-band pass filter
(FITC and Texas red) and triple-band pass filter (DAPI,
FITC, and Texas Red). Histological areas previously
selected in the HE-stained (hematoxylin and eosin) sec-
tions were identified in the hybridized slides. Signals
were scored in 100 epithelial nuclei per specimen, in at
least four distinct areas: 50 nuclei in the superficial layer
(larger cells, closer to the lumen) and 50 nuclei in the
basal layer (darker HE-stained nuclei, smaller cells, clo-
ser to the muscular layer). The scoring was performed
in both layers to check for differences between prolifer-
ate activity, since basal layer cells are in high prolifera-
tive activity, whereas the superficial layer cells are more
mature. For 3 genes, FHIT, EGFR and CDKN2A,t h e
experiments were performed including centromeric
sequences of carrier chromosomes as an internal con-
trol, respectively chromosomes 3, 7 and 9. This design
was necessary for FHIT and CDKN2A since these genes
are known for their loss in cancer specimens [21,22].
For each FISH probe set, tissue sections from two nor-
mal subjects were used as control.
Statistical Analysis
Descriptive statistics were calculated using an Microsoft
Excel macro template previously validated including
mean copy number per cell, standard deviation and fre-
quency of cells with 1, 2 and ≥3c o p i e so fe a c hD N A
target tested, as well as the ratio for gene/control probe
when applicable. The superficial and basal layers were
compared by t-student paired test, and between the
experimental groups were compared by t-student
unpaired test; in both cases confidence level was estab-
lished as 0.05 [23]. Association between gene status with
age, gender, life style factors (smoking and alcoholism),
and megaesophagus grade in the CM group was com-
pared by ANOVA and the comparisons for losses and
gains, and aneusomies, between the groups, were done
by c
2 test. One exploratory analysis using three-dimen-
sional plots was performed for the percentages of genes
status classes.
Results
The descriptive indexes (mean and standard deviation)
for the tested genes (FHIT, PIK3CA, TP63, EGFR,
FGFR1, MYC, CDKN2A, YES1, NCOA3) and centro-
meric sequences (chromosomes 3, 7 and 9 evaluated
respectively with the genes FHIT, EGFR and CDKN2A),
and the results of the statistical analyses for comparison
of mean copy numbers between the superficial and
basal layers in each group are presented in Table 1. The
mean values in the CM group ranged from 1.49 to 1.78
in the superficial layer and from 1.45 to 1.79 in the
basal layer. In the NM group, the mean frequencies ran-
ged from 1.35 to 1.77 in the superficial layer and from
1.61 to 1.79 in the basal layer. Superficial and basal
layers of the esophageal mucosa did not show significant
differences, excepted for EGFR in the CM group (p =
0.008) that showed lower copy number in the basal
layer. Results from both layers were combined for com-
parison of mean copy numbers per cell of the each
molecular target and no difference was detected
between CM and NM. However, the copy number of
CDKN2A was significantly lower (p < 0.0001) in the CM
g r o u pc o m p a r e dt oN M ,a n ds i m i l a rr e s u l t sw e r e
observed for the corresponding centromere 9 (CEP9)
(p = 0.0002).
In another investigative approach, frequencies of
nuclei with normal (2 copies) or loss (<2 copies) and
gain (>2 copies) for each gene were compared (Table 2),
and only for PIK3CA there were higher frequencies of
cells with copy number loss in the CM group compared
to NM (36.4% vs. 28.5%). Statistical analysis was not
performed for gain due to the scarcity of cells with this
pattern. Aneusomies involving centromeres of chromo-
somes 3, 7, and 9 were also investigated (Table 2). The
CM group showed significantly increased frequencies of
cells with copy number loss of centromeres of chromo-
somes 7 and 9 (51% and 44%, respectively) in compari-
son to the NM group (28% and 23%, respectively). The
CM group also showed numerically higher frequencies
of cells with copy number gain of centromeres of chro-
mosomes 7 and 9 (1.68% and 10.38%, respectively) than
the NM group (0.50% and none, respectively), although
the numbers were too small for statistical analyses.
The gene/centromere ratios for FHIT/CEN3,E G F R /
CEP7 and CDKN2A/CEP9, the probe sets including
matched targets in the study, were all balanced (close to
1) and differences were not detected between the mean
copy number of each target within each group
(Table 3). These results suggest that loss of FHIT, EGFR
and CDKN2A was accompanied by loss of their respec-
tive chromosomes.
Data were also subject to an exploratory analysis using
three-dimensional plots of the percentages of cells per
genomic pattern (loss, balanced and gain) for individual
cases as illustrated in Figure 1. Several cases were identi-
fied harboring deletions on specifics targets: CM7
(YES1), CM12 (CDKN2A), CM13 (PIK3CA; TP63),
CM19 (PIK3CA), CM30 (EGFR), CM36 (FHIT; CEP9),
CM16 and CM34 (CEP9). Other cases showed genomic
gain for specific targets: CM3 (MYC), CM6 (TP63;
MYC), CM7 (TP63), CM11 (PIK3CA; CDKN2A), CM16
(CDKN2A), CM28 (PIK3CA), CM30 (MYC; FGFR1),
CM36 (NCOA3), and CM11 and CM21 (CEP9). Figure 2
illustrates unbalanced status of genes and centromeric
DNA targets in megaesophagus specimens.
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between mean copy number per cell of each DNA target
tested and parameters such as age, gender and the life
style factors tobacco smoking and alcoholism although
the small size of each subset impaired robust conclu-
sion. Similarly, no significant differences were observed
on mean copy number per cell of each genomic target
according the dilation grades of megaesophagus (data
not shown). However, the CM cases identified with
genomics deletions and gains in the three-dimensional
plots were mostly classified as grades III and IV, sug-
gesting that chromosomal imbalances are more likely to
occur in more advanced grades.
Discussion
Esophageal squamous cell carcinoma is one of the most
prevalent cancers worldwide and has multifactorial ori-
gin, in which environment factors, especially alcohol
ingestion and smoking, play significant role [10,24]. Sev-
eral genetic alterations are also associated with ESCC,
such as chromosomal changes, allelic deletions, activa-
tion of oncogenes and inactivation of tumor suppressor
genes [10,11]. In tropical and subtropical countries of
Latin America such as Brazil, the risk of ESCC may also
be related to megaesophagus due to Chagas’ disease.
The period between onset of symptoms related to acha-
lasia and detection of cancer ranges from 17 to 28 years
[4]. In the current study no patient developed esopha-
geal carcinoma, which can also be due to insufficient
follow up.
This study showed that genomic copy number
changes were not common events in megaesophagus.
Among the tested 12 DNA targets mapped to 6 distinct
chromosomes, there was only marginal differences
between specimens from chagasic megaesophagus and
normal esophageal mucosa. The only statistically signifi-
cant difference in copy number between groups involved
CDKN2A.L o s so ff u n c t i o no fCDKN2A (also called
MTS-1 or P16) prevents the blocking of G1 phase and
appears to be a necessary event for the progression of
Table 1 Mean copy number per cell for the 12 DNA targets tested in esophageal mucosa of chagasic megaesophagus
and normal mucosa groups.
CM NM
Targets Mucosa Layers Mucosa Layers t-Student
CM × NM
Superficial Basal Total Superficial Basal Total
Mean ± SD Mean ± SD
FHIT 1.77 ± 0.08 1.78 ± 0.08 1.76 ± 0.08 1.35 ± 0.49 1.75 ± 0.04 1.74 ± 0.04
ns P = 0.7803
Range: 1.56-1.90 Range: 1.71-1.77
PIK3CA 1.76 ± 0.09 1.78 ± 0.08 1.77 ± 0.07 1.70 ± 0.09 1.78 ± 0.11 1.74 ± 0.01
ns P = 0.6982
Range: 1.56-1.96 Range: 1.64-1.86
TP63 1.77 ± 0.11 1.78 ± 0.09 1.77 ± 0.09 1.70 ± 0.09 1.78 ± 0.11 1.74 ± 0.01
ns P = 0.5304
Range: 1.56-2.06 Range: 1.64-1.86
EGFR 1.52 ± 0.12
a 1.45 ± 0.15
b 1.49 ± 0.13
a, b 1.60 ± 0.00 1.74 ± 0.01 1.67 ± 0.01
nsP = 0.3700
Range: 1.25-1.80 Range: 1.60-1.75
FGFR1 1.78 ± 0.01 1.76 ± 0.10 1.77 ± 0.08 1.63 ± 0.01 1.70 ± 0.03 1.67 ± 0.03
ns P = 0.2200
Range: 1.56-2.22 Range: 1.62-1.72
MYC 1.76 ± 0.09 1.75 ± 0.09 1.76 ± 0.08 1.66 ± 0.01 1.74 ± 0.02 1.70 ± 0.01
ns P = 0.5396
Range: 1.58-1.77 Range: 1.69-1.70
CDKN2A 1.49 ± 0.08 1.50 ± 0.07 1.50 ± 0.06 1.76 ± 0.14 1.72 ± 0.01 1.74 ± 0.07 * P < 0.0001
Range: 1.34-1.59 Range: 1.69-1.79
YES1 1.67 ± 0.13 1.67 ± 0.12 1.67 ± 0.11 1.70 ± 0.08 1.68 ± 0.13 1.69 ± 0.07
ns P = 0.8099
Range: 1.37-1.99 Range: 1.58-1.75
NCOA3 1.65 ± 0.11 1.64 ± 0.11 1.64 ± 0.10 1.66 ± 0.11 1.61 ± 0.01 1.64 ± 0.06
ns P = 0.7656
Range: 1.37-1.80 Range: 1.59-1.68
Centromere 3 1.77 ± 0.08 1.79 ± 0.07 1.77 ± 0.07 1.71 ± 0.07 1.76 ± 0.08 1.74 ± 0.08
nsP = 0.6638
Range: 1.56-1.90 Range: 1.68-1.79
Centromere 7 1.53 ± 0.12 1.50 ± 0.16 1.52 ± 0.13 1.67 ± 0.01 1.79 ± 0.04 1.73 ± 0.21
nsP = 0.1235
Range: 1.26-1.53 Range: 1.76-1.82
Centromere 9 1.53 ± 0.09 1.53 ± 0.09 1.53 ± 0.07 1.77 ± 0.15 1.77 ± 0.04 1.77 ± 0.10 * P = 0.0002
Range: 1.33-1.65 Range: 1.70-1.84
CM, chagasic megaesophagus; NM, normal mucosa; SD, standard-deviation; Statistical Analysis: t-Student; *, P < 0.05;
ns, P > 0.05;
a, b, P = 0.008.
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epigenetic alterations in CDKN2A have been reported in
early stages of esophageal carcinogenesis [27-30]. In pri-
mary esophageal carcinomas and cell lines, deletions
and point mutations in CDKN2A gene have been
reported in 16% to 82% of cases [22,31], and hyper-
methylation of promoter region in 20% to 88% of ESCC
and precancerous lesions [30,32]. The current study
detected deletion of CDKN2A and CEP 9 sequences in
CM compared with NM group. In agreement with these
findings, patients with idiopathic achalasia and chagasic
megaesophagus, with or without esophageal carcinoma,
showed reductions in expression of p16 protein [7] and
Bellini et al. [33] observed a marginal decrease in p16
protein expression in chagasic megaesophagus. Addi-
tionally, recent subset analyses by our group did not
find mutations in CDKN2A (exons 1 and 2) and FHIT
(exons 5 and 7) genes, suggesting these events are
uncommon in CM [34], and have detected copy number
changes of chromosomes 7, 11 and 17 and TP53 dele-
tion by FISH [35].
The tumor suppressor gene FHIT (3p14.2) is deregu-
lated during the development of ESCC. Deletion in both
FHIT alleles results in failure in the transcript [36] and
consequent absence or reduction of Fhit protein, which
act in the cell cycle regulation and apoptosis. Genetic
and epigenetic alterations of FHIT are associated with
development of several cancer types [37,38]. Loss of het-
erozygosity (LOH) in areas of the 3p14-p21 bands has
also been reported in low-grade dysplasia and postulated
as early events in esophageal carcinogenesis [39]. While
hypermethylation of FHIT gene has been described in
33% to 69.4% of ESCC cases, it is also known that dele-
tion and loss of protein expression are frequent in eso-
phageal carcinoma [32,36]. Deletion of FHIT observed
in a single megaesophagus specimen in the present
study may associate with early onset of genetic chances
in these lesions, but it is worth to note that no signifi-
cant decrease in the level of Fhit protein expression
have been detected in chagasic megaesophagus [33].
All other tested genes are categorized as oncogenes
and have been previously shown to associate with
ESCC, in which they are commonly amplified [12-19].
However, abnormal copy number patterns were only
seen in few individuals in the Chagasic megasophagus
Table 2 Frequencies of cells with loss, normal status and
gain in copy numbers of the target in chagasic
megaesophagus and normal mucosa groups.
<2 copies per cell 2 copies per
cell
>2 copies per
cell
Target CM NM c
2test CM NM CM NM
FHIT
N 20 2 P = 10.672
ns 2478 144 6 3
% 0.79 1.34 98.96 96.64 0.24 2.04
PIK3CA
N 898 57 P = 0.000* 1530 139 35 4
% 36.39 28.50 61.99 69.50 1.42 2.00
TP63
N 885 58 P = 2.579
ns 2878 136 37 6
% 23.29 29.00 75.74 68.00 0.97 3.00
EGFR
N 298 12 P = 1.067
ns 3433 187 171 1
% 7.59 6.00 88.03 93.50 4.38 0.50
FGFR1
N 928 68 P = 4.172
ns 2833 121 46 1
% 24.38 34.00 74.41 60.50 1.21 0.50
MYC
N 918 62 P = 4.812
ns 2849 135 33 2
% 24.00 31 75.00 67.50 0.01 1.00
CDKN2A
N 183 6 P = 17.702
ns 3649 194 68 0
% 4.69 3.00 93.56 97.00 1.74 0.00
YES1
N 1381 62 P = 2.171
ns 2407 136 12 2
% 36.34 31.00 63.34 68.00 0.32 1.00
NCOA3
N 45 8 P = 3.627
ns 2366 130 8 0
% 1.86 5.80 97.81 94.20 0.33 0.00
CEN3
N 683 54 P = 0.470
ns 2510 145 7 1
% 21.0 27.0 78.44 72.5 0.56 0.50
CEP7
N 1637 56 P = 0.00+* 1509 1143 54 1
% 51.16 28.0 47.16 71.50 1.68 0.50
CEP9
N 1400 46 P = 0.00+* 1468 154 332 0
% 43.75 23.0 45.87 77.0 10.38 0.00
CM, chagasic megaesophagus; NM, normal mucosa; SD, standard-deviation;
Statistical Analysis: t-Student; *, P < 0.05;
ns, P > 0.05;
a, b, P = 0.008.
Table 3 Comparison between matched gene and
centromere targets, in chagasic megaesophagus and
normal mucosa groups.
Gene-Centromere CM NM
Mean ± SD Ratio Mean ± SD Ratio
FHIT 1.77 ± 0.08 1.00 1.74 ± 0.04 1.00
CEN3 1.77 ± 0.08 1.74 ± 0.08
t-Student ns ns
EGFR 1.49 ± 0.12 0.98 1.67 ± 0.01 0.96
CEP7 1.51 ± 0.13 1.73 ± 0.02
t-Student ns ns
CDKN2A 1.51 ± 0.09 1.00 1.74 ± 0.07 0.98
CEP9 1.54 ± 0.10 1.77 ± 0.10
t-Student ns ns
Chagasic megaesophagus, CM; normal mucosa, NM; SD, standard-deviation;
Statistical Analysis: t-Student ns, p > 0.05.
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is PIK3CA, which encodes the catalytic subunit that
uses ATP to phosphorylate phosphatidylinositol, a gene
that is frequently amplified in ESCC [40-42]. Yen et al.
[40] determined in FISH assays that PIK3CA was ampli-
fied in cell lines and primary tumors and detected a
positive correlation between amplification and tumor
size, lymph node metastasis and clinical stage. Yang et
al. [41] showed that PIK3CA gene amplification was
highly correlated with protein overexpression, support-
ing amplification as a major mechanism for overexpres-
sion. Nevertheless, in this study PIK3CA was lost rather
than amplified in the CM specimens as a group while
involved in marginal level of loss two specimens and
gained in two other specimens.
Gene amplification was one of the basic mechanisms
leading to overexpression of the TP63 in ESCC
[18,43,44]. The amplification of TP63,w h o s ep r o t e i n
Figure 1 Exploratory analysis using three-dimensional plots of the percentages of genes status for individual cases is illustrated.R e d
square: Normal Mucosa; Green Square: Megaesophagus, A. EGFR, Mean frequency of loss in the CM = 6.84%, CM30 ~30% of loss; B. FHIT, Mean
frequency of loss in the CM = 0.63%, CM36 ~10% of loss; C. PIK3CA, Mean frequency of loss: 23.63%, Mean frequency of gain: 0.92%, CM13 and
CM19 ~40% of loss, CM28 and CM11, between 5 and 10% of gain; D. TP63, Mean frequency of loss = 23.29%, Mean frequency of gain = 1.07%,
CM13 ~45% of loss, CM6 and CM7 ~10% of gain; E. CDKN2A, Mean frequency of loss = 4.76%, Mean frequency of gain = 1.79%, CM12 ~12% of
loss, CM 11 and CM 16 ~6% of gain; F. MYC, Mean frequency of gain = 0.87%, CM3, CM6 and CM30 between 5 and 7.5% of gain.
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epithelial tissues has been described in early stage of
ESCC carcinogenesis but down-regulated in advanced
[18,43]. Amplification of the membrane receptor genes
EGFR and FGFR1 has been reported in various cancers
including ESCC [45,46], and this phenomenon has been
suggested to be a poor prognostic factor in solid tumors
[47]. In ESCC, co-expression of both aFGF and FGFR1
was associated with larger tumor area and worse prog-
nosis which suggests that the membrane receptor may
promote proliferation of esophageal cancer cells in an
angiogenesis-independent and autocrine manner and
may contribute to rapid recurrence after esophageal
resection [47].
MYC is a transcription factor that binds E-boxes as a
heterodimer with Max in about 15% of all genes, and
recruits co-activators to regulate gene transcription.
MYC is regulated in part through mitogenic stimuli and
is activated constitutively in cancer cells through gene
amplification, chromosomal translocation, point muta-
tion and mitogenic stimulation [48]. MYC was found to
be amplified in ESCC cell lines and in primary tumors
[14]. YES1 codes a protein with tyrosine kinase activity
that has been previously associated with esophageal car-
cinogenesis [15,42]. Similarly, the NCOA3 gene encod-
ing a nuclear receptor coactivator that interacts with
nuclear hormone receptors to enhance their transcrip-
tional activator function was found frequently overex-
pressed and also amplified in 5 to 15% of ESCCs
[49-51].
Although is well established that megaesophagus pre-
ferentially affects males between the second and fourth
decades of life [3], this study has not detected relation-
ship between copy numbers of each tested gene and
parameters such as age, gender, life style factors
(tobacco smoking and alcoholism) and megaesophagus
grade in the CM group. Nevertheless these findings may
have been impacted by the limited number of samples
in each category.
Interestingly, specimens with genomics deletions and
gains exhibited mostly more advanced dilation grades.
Megaesophagus patients have high variety of esophageal
microbiota, which consists mainly of Gram-positive
anaerobic bacteria in concentrations that correlated with
the degree of esophageal dilation [6,52]. Bacteria in fluid
stasis can undergo reduction from nitrates to nitrites
Figure 2 FISH images for the unbalanced genes and centromeric targets in the megaesophagus specimens. Dual-target, dual-color color
hybridization in chagasic megaesophagus. A. Loss of CDKN2A (red signal) and centromere 9 (green signal); B. Loss of EGFR (red signal) and
centromere 7 (green signal); C. Loss of FHIT (red signal) and centromere 3 (green signal); D. Gain of TP63 (red signal) and loss of PIK3CA (green
signal). Arrows indicated cells with abnormal copy numbers of the genes.
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potent action in esophageal carcinogenesis [52]. High
grade megaesophagus present higher dilation and eso-
phageal stasis associated with bacterial proliferation,
thus the data suggest that the level of dilation and
inflammation of megaesophagus could promote genetic
damages and could be related to increased risk of tumor
development [4,7,53].
Conclusion
In conclusion, among 40 chagasic megaesophagus com-
prehensively investigated with a panel of FISH probes,
copy number gain was only displayed by three speci-
mens for MYC, by one specimen for FGFR1 and one
specimen for NCOA3.L o s so fFHIT and YES1 was seen
in one specimen and of EGFR in another. For the
remainder genes CDKN2A, PIK3CA and TP63, from one
to four specimens each showed copy number gain or
loss. In every case the difference was only marginal
therefore not providing strong support to a biological
impact. These findings show that imbalances involving
the genomic regions encompassing gene sequences
relevant in esophageal carcinogenesis were not found as
significant events in chagasic megaesophagus. Conse-
quently, genomic imbalances are not promising markers
for assessment of ESCC risk in chagasic megaesophagus.
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